Abstract
The effects of 1% lidocaine as a diluent on the pharmacokinetics and tolerance of ceftriaxone administered intramuscularly were investigated in 12 adult volunteers. Each subject received two 0.5-g doses of ceftriaxone (one in water and the other in 1% lidocaine) at least 1 week apart in a randomized crossover fashion. Plasma and urine samples were collected serially and assayed for ceftriaxone content by high-performance liquid chromatography. The mean peak plasma concentration, time to attain the peak, area under the plasma curve from time zero to infinity, and elimination half-life were 45 micrograms/ml, 2.5 h, 578 micrograms . h/ml, and 7.1 h, respectively, after intramuscular administration of ceftriaxone in water diluent. The corresponding mean values in 1% lidocaine diluent were 42 micrograms/ml, 3 h, 577 micrograms . h/ml, and 7.0 h. The pharmacokinetic data suggested that 1% lidocaine does not alter either the elimination parameters or the bioavailability of intramuscularly administered ceftriaxone. The intensity and frequency of pain at the injection site were reduced considerably by the coadministered lidocaine.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Benowitz N. L., Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet. 1978 May-Jun;3(3):177–201. doi: 10.2165/00003088-197803030-00001. [DOI] [PubMed] [Google Scholar]
- Foster T. S., Shrewsbury R. P., Coonrod J. D. Bioavailability and pain study of cefamandole nafate. J Clin Pharmacol. 1980 Aug-Sep;20(8-9):526–533. doi: 10.1002/j.1552-4604.1980.tb02546.x. [DOI] [PubMed] [Google Scholar]
- Greenblatt D. J., Koch-Weser J. Intramuscular injection of drugs. N Engl J Med. 1976 Sep 2;295(10):542–546. doi: 10.1056/NEJM197609022951006. [DOI] [PubMed] [Google Scholar]
- Patel I. H., Chen S., Parsonnet M., Hackman M. R., Brooks M. A., Konikoff J., Kaplan S. A. Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother. 1981 Nov;20(5):634–641. doi: 10.1128/aac.20.5.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Patel I. H., Miller K., Weinfeld R., Spicehandler J. Multiple intravenous dose pharmacokinetics of ceftriaxone in man. Chemotherapy. 1981;27 (Suppl 1):47–56. doi: 10.1159/000238029. [DOI] [PubMed] [Google Scholar]
- Pickup M. E., Bird H. A., Lowe J. R., Lees L., Wright V. A pharmacokinetic and tolerance study of Ro13-9904, a new cephalosporin antibiotic. Br J Clin Pharmacol. 1981 Aug;12(2):111–115. doi: 10.1111/j.1365-2125.1981.tb01188.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Seddon M., Wise R., Gillett A. P., Livingston R. Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1980 Aug;18(2):240–242. doi: 10.1128/aac.18.2.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sonneville P. F., Albert K. S., Skeggs H., Gentner H., Kwan K. C., Martin C. M. Effect of lidocaine on the absorption, disposition and tolerance of intramuscularly administered cefoxitin. Eur J Clin Pharmacol. 1977 Dec 2;12(4):273–279. doi: 10.1007/BF00607426. [DOI] [PubMed] [Google Scholar]
- Stoeckel K., McNamara P. J., Brandt R., Plozza-Nottebrock H., Ziegler W. H. Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther. 1981 May;29(5):650–657. doi: 10.1038/clpt.1981.90. [DOI] [PubMed] [Google Scholar]
- Stoeckel K. Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life. Chemotherapy. 1981;27 (Suppl 1):42–46. doi: 10.1159/000238028. [DOI] [PubMed] [Google Scholar]
- WAGNER J. G., NELSON E. Per cent absorbed time plots derived from blood level and/or urinary excretion data. J Pharm Sci. 1963 Jun;52:610–611. doi: 10.1002/jps.2600520629. [DOI] [PubMed] [Google Scholar]